IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $751.00 Average Price Target from Analysts

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $751.00.

IDXX has been the topic of several analyst reports. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. UBS Group dropped their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock.

Institutional Trading of IDEXX Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in IDEXX Laboratories by 2.5% in the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the last quarter. Harbour Investments Inc. grew its position in IDEXX Laboratories by 13.3% in the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after acquiring an additional 16 shares during the period. CWA Asset Management Group LLC increased its stake in IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after acquiring an additional 17 shares during the last quarter. Rockland Trust Co. increased its stake in IDEXX Laboratories by 4.4% during the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after acquiring an additional 18 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC raised its position in IDEXX Laboratories by 0.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after purchasing an additional 18 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $557.80 on Friday. IDEXX Laboratories has a one year low of $506.91 and a one year high of $769.98. The stock has a market cap of $44.00 billion, a PE ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a 50 day moving average price of $555.31 and a 200 day moving average price of $609.16.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.